N-Acylhydrazone Metal-Protein Attenuators for Protein Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's, Parkinson's disease, type 2 diabetes, and cataracts are palliative and do not reverse the damage caused by protein aggregation, with existing Metal-Protein Attenuating Compounds (MPACs) showing clinical inefficacy and side effects.
Innovation Solution
Development of N-acylhydrazones structurally derived from 1-methyl-1H-imidazole-2-carboxaldehyde that act as MPACs, competing with physiological metal ions to prevent protein oligomerization and modulate protein-protein interactions, thereby reducing oxidative stress and aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current treatments are used for Alzheimer's and Parkinson's diseases, then the progress of the disease is slowed down, but the damage already suffered cannot be reversed and the treatments are palliative only
Solution Approach 1:
The N-acylhydrazones are designed to prevent protein aggregation before it occurs by binding to metal ions and interfering with the nucleation phase of aggregation. This preliminary action targets the early formation of soluble oligomers, preventing the cascade that leads to irreversible fibril formation and neuronal damage.
Solution Approach 2:
The N-acylhydrazones act as intermediary compounds that bind to metal ions (copper, zinc) and prevent these metals from catalyzing protein aggregation. The compounds serve as a mediating layer between the metal ions and the amyloidogenic proteins, disrupting the harmful interaction without directly targeting the proteins themselves.
2Object-affected harmful factors
If existing MPACs are used to prevent protein aggregation, then some aggregation prevention is achieved, but clinical inefficacy and side effects occur
Solution Approach 1:
The N-acylhydrazones modify the chemical parameters of metal ion binding by introducing specific functional groups (hydrazide, imidazole) that optimize binding affinity and selectivity. These parameter changes in molecular structure lead to improved pharmacological properties including better blood-brain barrier penetration and reduced off-target effects.
Solution Approach 2:
The compounds combine multiple functional moieties (N-acylhydrazone group, imidazole ring, aromatic substituents) into a composite molecular structure that simultaneously provides metal binding capability, membrane permeability, and selective affinity for amyloidogenic proteins, achieving synergistic therapeutic effects.
3Object-affected harmful factors
If metal ion binding is increased to enhance aggregation prevention, then protein aggregation is reduced, but oxidative stress may increase due to metal dyshomeostasis
Solution Approach 1:
The N-acylhydrazones serve as intermediary chelators that bind to metal ions and prevent them from catalyzing both protein aggregation and harmful Fenton reactions. By sequestering the metals in a stable complex, the compounds eliminate the dual pathway of harm (aggregation and oxidative stress) without depleting essential metal pools.
Solution Approach 2:
The compounds convert the harmful presence of excess metal ions into a beneficial effect by using the metals' affinity for the hydrazone group to create stable, non-toxic complexes. The same metal ions that would normally promote aggregation and oxidative stress are instead utilized to form protective complexes that prevent both pathways of damage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The N-acylhydrazones effectively reduce protein aggregation and oxidative stress, offering a potential therapeutic option for a wide range of degenerative diseases, including Alzheimer's, Parkinson's, type 2 diabetes, and cataracts, with improved solubility and stability over existing compounds.
Implementation Method 1
acting as MPACs, competing with physiological metal ions to prevent protein oligomerization
Implementation Method 2
reducing oxidative stress and aggregation
Data Source
AI summary
The present invention relates to a family of N-acylhydrazonic compounds structurally derived from 1-methyl-1H-imidazole-2-carboxaldehyde, or pharmaceutically acceptable salts thereof, and the use of said compounds to prevent and/or treat amyloid (such as Alzheimer's, Parkinson's and type 2 diabetes) and non-amyloid (such as cataracts) degenerative aggregopathies These compounds act as attenuators of the metal-protein interaction, preventing and/or decreasing protein oligomerization through competition with the target peptide or protein for the binding of physiological metal ions and, possibly, by modulating the protein-protein interaction itself. The invention also details four compounds specifically described as examples of N-acylhydrazones derived from 1-methyl-1H-imidazole-2-carboxaldehyde, namely: 1-methyl-1H-imidazole-2-carboxaldehyde isonicotinoyl hydrazone, 1-methyl-1H-imidazole-2-carboxaldehyde benzoyl hydrazone, 1-methyl-1H-imidazole-2-carboxaldehyde 2-furoyl hydrazone and 1-methyl-1H-imidazole-2-carboxaldehyde 2-thiophenyl hydrazone. The current application also comprises pharmaceutical compositions.